PRESSEMITTEILUNGEN

——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/molecular diagnostics 09.12.2011 Berlin, Germany, December 9, 2011 – Epigenomics AG (ISIN: DE000A1K0516) reports the completion of the clinical validation study [...]

Continue reading

Berlin Germany, Cancer Cases, Clinical Performance, Clinical Validation, Colonoscopy, Colorectal, Colorectal Cancer, Disease Specificity, Epigenomics Ag, Food And Drug Administration, Food And Drug Administration Fda, German Securities Trading Act, Independent Laboratories, Molecular Diagnostics, Plasma Samples, Regulatory Approval, Screening Guidelines, Securities Trading Act, Study Subjects, Validation Study

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/New Products/molecular diagnostics Subtitle: Conference Call Scheduled for today, 9thDecember 2011 at 4 pm CET Berlin, Germany, and Seattle, WA, U.S.A., December 9, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer [...]

Continue reading

Adhoc, Berlin Germany, Cancer Cases, Clinical Performance, Clinical Validation, Colonoscopy, Colorectal, Colorectal Cancer, Diagnostic Company, Disease Specificity, Eans, Epigenomics Ag, Independent Laboratories, Molecular Diagnostics, Plasma Samples, Prime Standard, Regulatory Approval, Screening Guidelines, Study Subjects, Validation Study

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Company Information/molecular diagnostics Subtitle: Epigenomics to host a corporate workshop on advances in blood-based colorectal cancer screening; ARUP Laboratories will present independent data for its laboratory-developed Septin9 test Grapevine, TX, U.S.A., November 16, 2011 (euro [...]

Continue reading

Adjunct Assistant Professor, American Cancer, Arup Laboratories, Biomarker, Cancer Cases, Cancer Screening, Colorectal Cancer, Corporate Workshop, Epigenomics Ag, Grapevine Texas, Grapevine Tx, Independent Data, Interpretation Algorithm, Ldt, Molecular Diagnostics, Molecular Pathology, Plasma Marker, Test Interpretation, University Of Utah School Of Medicine, Utah School

——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Neue Produkte/Unternehmen/molekulardiagnostik Utl.: Epigenomics veranstaltet Workshop zu den Fortschritten bei der blutbasierten Darmkrebs-Früherkennung; ARUP Laboratories präsentiert unabhängige Daten zu ihrem laborentwickelten Septin9-Tests Grapevine, TX, USA, 16. November 2011 (euro adhoc) – Epigenomics AG, das deutsch-amerikanische Krebsdiagnostik-Unternehmen, gab heute bekannt, dass [...]

Continue reading

16 November, Adhoc, Adjunct Assistant Professor, Arup Laboratories, Corporate News, Darmkrebs, Deutsch Amerikanische, Dr Karen, Epigenomics Ag, Grapevine Texas, Grapevine Tx, Klinische, Molecular Pathology, Neue Produkte, School Of Medicine, Technology Development, University Of Utah, University Of Utah School Of Medicine, Utah School, Utl

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– Company Information/9-month report/molecular diagnostic Subtitle: Main focus for Q4: to successfully file PMA with the FDA in the US and simultaneous re-launch in Europe with dramatically improved Epi proColon® 2.0 CE test Berlin, Germany, and Seattle, [...]

Continue reading

Adhoc, Berlin Germany, Chief Executive Officer, Diagnostic Company, Eans, Epigenomics Ag, Food And Drug Administration, Food And Drug Administration Fda, Generation Product, Launch, Market Key, Operational Challenges, Pivotal Study, Premarket Approval, Prime Standard, Quarter Performance, S Market, Seattle Wa, Turbulent Financial Markets, Validation Studies

——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Neue Produkte/Unternehmen/Molekulardiagnostik Utl.: Vorstellung des leistungsstarken Darmkrebs-Bluttests der zweiten Generation auf der UEGW in Stockholm Berlin, Deutschland und Stockholm, Schweden, 25. Oktober 2011 (euro adhoc) – Das Krebsdiagnostik-Unternehmen Epigenomics AG (Frankfurt Prime Standard: ECX) gab heute die bevorstehende Markteinführung von [...]

Continue reading

Adhoc, Berlin, Corporate News, Deutschland, Ecx, Epigenomics Ag, Euro, Europa, European Gastroenterology, Frankfurt, Krebs, Prime Standard, Sein, Stockholm, Uegw, United

——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– New Products/Company Information/molecular diagnostics Subtitle: Presentation of the powerful second generation blood test for colorectal cancer screening during UEGW in Stockholm Berlin, Germany, and Stockholm, Sweden, October 25, 2011 (euro adhoc) – Epigenomics AG (Frankfurt Prime [...]

Continue reading

Adhoc, Berlin Germany, Blood Test, Cancer Detection, Cancer Screening, Clinical Validation, Colorectal, Colorectal Cancer, Epigenomics Ag, European Gastroenterology, Invasive Method, Launch, Molecular Diagnostics, New Test, Positive Predictive Value, Ppv, Prime Standard, Second Generation, Stockholm Sweden, Uegw

——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Unternehmen/Neue Produkte/Molekulardiagnostik Utl.: Studie liefert klinische Daten für CE-Kennzeichnung in Europa und ebnet Weg für US-Zulassungsstudie; FDA-Zulassungsantrag soll noch 2011 gestellt werden Berlin, Deutschland und Seattle, WA, USA, 19. September 2011 (euro adhoc) – Das Krebsdiagnostik-Unternehmen Epigenomics AG (Frankfurt Prime [...]

Continue reading

19 September, Adhoc, Berlin, Corporate News, Darmkrebs, Deutschland, Ebnet, Ecx, Epigenomics Ag, Euro, Fda, Frankfurt, Kennzeichnung, Klinische, Klinischen, Krebs, Neue Produkte, Prime Standard, Seattle Wa Usa, Utl

——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Company Information/molecular diagnostic 10.08.2011 Berlin, Germany, and Seattle, WA, U.S.A., August 10, 2011 – Epigenomics AG (ISIN: DE000A1K0516) today released plans to [...]

Continue reading

August 10, Berlin Germany, Blood Test, Colorectal, Commercial Opportunity, Commercialization, Epigenomics Ag, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, German Securities Trading Act, Isin, Key Accounts, Launch Research, Market Operations, S Market, Seattle Wa, Second Generation, Securities Trading Act, Year End

——————————————————————————– Ad-hoc-Meldung nach § 15 WpHG übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. ——————————————————————————– Unternehmen/Molekulardiagnostik 28.06.2011 Berlin, Deutschland 28. Juni 2011 – Die Hauptversammlung der Epigenomics AG (ISIN: DE000A0BVT96) stimmte am heutigen Tag allen Vorschlägen der Verwaltung mit großer Mehrheit zu. Für den Vorschlag der [...]

Continue reading

Achim, Ad Hoc, Adhoc, Aktien, Berlin, Eans, Epigenomics Ag, Euro, Investor Relations, Investors, Isin, Kontakt, Mit, Plum, Tag, Verwaltung, Vp, Www News

——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Company Information/molecular diagnostic 28.06.2011 Berlin, Germany, June 28, 2011 – Epigenomics AG`s (ISIN: DE000A0BVT96) General Assembly today approved all decision proposals by [...]

Continue reading

Achim, Adhoc, Aim, Berlin Germany, Commercial Register, Disclosure, Eans, Epigenomics Ag, General Assembly, Investor Relations, Isin, Legal Disclaimers, Plum, Proposals, Share Capital, Shareholder, Uncertainties, Voting Results, Voting Rights, Vp

——————————————————————————– Information zur Hauptversammlung übermittelt durch euro adhoc. Für den Inhalt ist der Emittent verantwortlich. ——————————————————————————– HTML Version finden Sie unter folgendem Link. http://resources.euroadhoc.com/us/qmuiQ4OD Emittent : Epigenomics AG … : Kleine Präsidentenstr. 1 … : 10178 Berlin … : de Telefon : +49 30 243450 FAX : +49 30 2434555 Email : ir@epigenomics.com Tag der [...]

Continue reading

Berlin Hamburg, De Euro, Der Euro, Eans, Email, Epigenomics Ag, Frankfurt, Frankfurter, Isin, Prime Standard, Share Technology, Sprache Deutsch, Stuttgart

QIAGEN erwirbt Option auf den Biomarker mSEPT9 und DNA-Methylierungs-Technologien und erhält F&E-Lizenz für Forschung an Septin9-Produkten ——————————————————————————– Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. ——————————————————————————– Joint Ventures/Kooperationen/Zusammenarbeit/Neue Produkte/Molekulardiagnostik Utl.: QIAGEN erwirbt Option auf den Biomarker mSEPT9 und DNA-Methylierungs-Technologien und erhält F&E-Lizenz für Forschung an Septin9-Produkten Berlin und Seattle (USA), [...]

Continue reading

Adhoc, Amp, Berlin, Corporate News, Dna, Ecx, Epigenomics Ag, Euro, Frankfurt, Joint Ventures, Nasdaq, Neue Produkte, Prime Standard, Qgen, Qiagen, Seattle Usa, Technologien, Utl

——————————————————————————– ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. ——————————————————————————– New Products/Molecular diagnostics 28.02.2011 Berlin, Germany, February 28, 2011 – Epigenomics AG (ISIN: DE000A0BVT96) today signed an option agreement in colorectal cancer [...]

Continue reading

Amp, Berlin Germany, Biomarker, Biomarkers, Blood Test, Blood Testing, Collaboration Agreement, Collection Of Clinical Specimens, Colorectal, Colorectal Cancer, Dna Methylation, Epigenomics Ag, German Securities Trading Act, Isin, Molecular Diagnostics, Option Agreement, Qiagen, Sample Preparation, Securities Trading Act, Upfront Payment